Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease

References

• Bataille R, Chappard D, Marcelli C, et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989;7:1909–1914.
   PubMed Web of Science ®Google Scholar
• Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19–39.
   PubMed Web of Science ®Google Scholar
• Haaber J, Abildgaard N, Knudsen LM, et al. Myeloma cell expression of 10 candidate genes for osteolytic bone disease. Only overexpression of DKK1 correlates with clinical bone involvement at diagnosis. Br J Haematol 2008;140:25–35.
   PubMed Web of Science ®Google Scholar
• Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483–2494.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Morandi F, Tagliaferri S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res 2007;67:7665–7674.
   PubMed Web of Science ®Google Scholar
• Oshima T, Abe M, Asano J, et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106:3160–3165.
   PubMed Web of Science ®Google Scholar
• Kristensen IB, Haaber J, Lyng MB, et al. Myeloma plasma cell expression of osteoblast regulatory genes: overexpression of SFRP3 correlates with clinical bone involvement at diagnosis. Leuk Lymphoma 2013;54:425–427.
   PubMed Web of Science ®Google Scholar
• Terpos E, Christoulas D, Katodritou E, et al. Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer 2012;131:1466–1471.
   PubMed Web of Science ®Google Scholar
• Cho SW, Yang JY, Sun HJ, et al. Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone 2009;44:1069–1077.
   PubMed Web of Science ®Google Scholar
• Pearse RN, Sordillo EM, Yaccoby S, et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001;98:11581–11586.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Colla S, Rizzoli V. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). Exp Hematol 2004;32:685–691.
   PubMed Web of Science ®Google Scholar
• Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 2009;27:1564–1571.
   PubMed Web of Science ®Google Scholar
• Kawano Y, Ueno S, Abe M, et al. TRAIL produced from multiple myeloma cells is associated with osteolytic markers. Oncol Rep 2012;27:39–44.
   PubMed Web of Science ®Google Scholar
• Roodman GD, Choi SJ. MIP-1 alpha and myeloma bone disease. Cancer Treat Res 2004;118:83–100.
   PubMedGoogle Scholar
• Terpos E, Politou M, Szydlo R, et al. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003;123:106–109.
   PubMed Web of Science ®Google Scholar
• Terpos E, Dimopoulos MA, Sezer O, et al. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia 2010;24:1700–1712.
   PubMed Web of Science ®Google Scholar
• Kristensen IB, Christensen JH, Lyng MB, et al. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease. Br J Haematol 2013;161:373–382.
   PubMed Web of Science ®Google Scholar
• De VJ, Couderc G, Tarte K, et al. Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays. Blood 2001;98:771–780.
   PubMed Web of Science ®Google Scholar
• Moreaux J, Klein B, Bataille R, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica 2011; 96:574–582.
   PubMed Web of Science ®Google Scholar
• Qiang YW, Endo Y, Rubin JS, et al. Wnt signaling in B-cell neoplasia. Oncogene 2003;22:1536–1545.
   PubMed Web of Science ®Google Scholar
• Ling L, Nurcombe V, Cool SM. Wnt signaling controls the fate of mesenchymal stem cells. Gene 2009;433:1–7.
   PubMed Web of Science ®Google Scholar
• Chung YS, Baylink DJ, Srivastava AK, et al. Effects of secreted frizzled-related protein 3 on osteoblasts in vitro. J Bone Miner Res 2004;19:1395–1402.
   PubMed Web of Science ®Google Scholar
• Essex SJ, Seetharam A, Barkhuizen A et al. Stable epigenetic reprogramming of bone marrow mesechymal stromal cells is seen in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk 2013;13(Suppl.):S37 [abstract].
   Google Scholar
• Colucci S, Brunetti G, Oranger A, et al. Myeloma cells suppress osteoblasts through sclerostin secretion. Blood Cancer J 2011;1:e27.
   PubMed Web of Science ®Google Scholar
• Standal T, Abildgaard N, Fagerli UM, et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 2007;109:3024–3030.
   PubMed Web of Science ®Google Scholar
• Karner E, Unger C, Cerny R, et al. Differentiation of human embryonic stem cells into osteogenic or hematopoietic lineages: a dose-dependent effect of osterix over-expression. J Cell Physiol 2009; 218:323–333.
   PubMed Web of Science ®Google Scholar
• Colla S, Morandi F, Lazzaretti M, et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005;19:2166–2176.
   PubMed Web of Science ®Google Scholar
• Bataille R, Chappard D, Marcelli C, et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 1991;88: 62–66.
   PubMed Web of Science ®Google Scholar
• Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527–3533.
   PubMed Web of Science ®Google Scholar
• Lai FP, Cole-Sinclair M, Cheng WJ, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004;126:192–201.
   PubMed Web of Science ®Google Scholar
• Roux S, Meignin V, Quillard J, et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 2002;117:86–92.
   PubMed Web of Science ®Google Scholar
• Qiang YW, Chen Y, Stephens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood 2008;112:196–207.
   PubMed Web of Science ®Google Scholar
• Seidel C, Hjertner O, Abildgaard N, et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 2001;98:2269–2271.
   PubMed Web of Science ®Google Scholar
• Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 2002; 100:3002–3007.
   PubMed Web of Science ®Google Scholar
• Abe M, Hiura K, Wilde J, et al. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 2002;100:2195–2202.
   PubMed Web of Science ®Google Scholar
• Choi SJ, Cruz JC, Craig F, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000;96:671–675.
   PubMed Web of Science ®Google Scholar
• Roussou M, Tasidou A, Dimopoulos MA, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia 2009;23:2177–2181.
   PubMed Web of Science ®Google Scholar
• Uneda S, Hata H, Matsuno F, et al. Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 2003;120:53–55.
   PubMed Web of Science ®Google Scholar